88791-07-5

Basic information

• Product Name: 7-Methoxybenzo[b]thiophene-2-carboxylic acid
• Synonyms: 7-Methoxybenzo[b]thiophene-2-carboxylic acid;7-Methoxy-1-benzothiophene-2-carboxylic acid
• CAS NO: 88791-07-5
• Molecular Formula: C₁₀H₈O₃S
• Molecular Weight: 208.23372
• Mol File: 88791-07-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 410°C at 760 mmHg
• Flash Point: 201.8°C
• Appearance: /
• Density: 1.392g/cm³
• Vapor Pressure: 1.86E-07mmHg at 25°C
• Refractive Index: 1.673
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 7-Methoxybenzo[b]thiophene-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Methoxybenzo[b]thiophene-2-carboxylic acid(88791-07-5)
• EPA Substance Registry System: 7-Methoxybenzo[b]thiophene-2-carboxylic acid(88791-07-5)

Safety Data

• Hazardous Substances Data: 88791-07-5(Hazardous Substances Data)

Usage

General Description

7-Methoxybenzo[b]thiophene-2-carboxylic acid is a chemical compound with the molecular formula C11H8O3S. It is a derivative of benzo[b]thiophene and contains a carboxylic acid functional group. 7-Methoxybenzo[b]thiophene-2-carboxylic acid is commonly used in organic chemistry research and drug discovery due to its potential pharmacological and biological properties. It may also have applications in the development of new drugs and pharmaceutical products. It is important to handle and use this compound with proper safety precautions and in accordance with applicable regulations and guidelines for handling potentially hazardous chemicals.

InChI:InChI=1/C10H8O3S/c1-13-7-4-2-3-6-5-8(10(11)12)14-9(6)7/h2-5H,1H3,(H,11,12)

Upstream product

• 88791-06-4 (2-formyl-6-methoxyphenylthio)acetic acid 
• 103438-88-6 2-fluoro-3-methoxybenzaldehyde 
• 88791-17-7 methyl 7-methoxybenzothiophene-2-carboxylate 
• 550998-65-7 methyl 7-cyanobenzo[b]thiophene-2-carboxylate 
• 165187-24-6 2-chloro-3-cyano-benzaldehyde 
• 88791-04-2 S-(2-formyl-6-methoxyphenyl)-N,N-dimethylthiocarbamate 
• 88791-03-1 O-(2-formyl-6-methoxyphenyl)-N,N-dimethylthiocarbamate 
• 88791-05-3 2-mercapto-3-methoxybenzaldehyde 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 
• 3926-62-3 sodium monochloroacetic acid 

Downstream Products

• 77898-35-2 7-hydroxybenzo[b]thiophene 
• 88791-12-2 4-bromo-7-methoxybenzothiophene 
• 1603136-48-6 C₂₁H₂₅FN₂O₄S₂ 
• 1603136-47-5 C₂₅H₃₃FN₂O₅S₃ 
• 1312608-59-5 C₄₃H₅₂N₈O₆S 
• 1312610-32-4 C₃₉H₄₆N₆O₄S 
• 1312610-31-3 C₂₇H₃₄B₂O₄S 
• 1312610-30-2 C₁₇H₁₀F₆O₆S₃ 
• 1312610-29-9 C₁₅H₁₂O₂S 
• 1312610-28-8 C₁₇H₁₆O₂S 
• 1312608-58-4 C₄₂H₅₀N₈O₆S 
• 1312610-06-2 C₂₈H₂₈N₆S 
• 1312610-05-1 C₃₈H₄₄N₆O₄S 
• 1312610-04-0 C₂₆H₃₂B₂O₄S 

Relevant articles and documents

Design, synthesis, and biological evaluation of benzo[b]thiophene 1,1-dioxide derivatives as potent STAT3 inhibitors

As a member of the signal transducer and activator of transcription (STAT) family, STAT3 plays a critical role in several biological pathways such as cell proliferation, migration, survival, and differentiation. Due to abnormal continuous activation in tumors, inhibition of STAT3 has emerged as an attractive approach for the treatment of various cancer cells. Herein, we report a series of novel STAT3 inhibitors based on benzo[b]thiophene 1,1-dioxide scaffold and evaluated their anticancer potency. Among them, compound 8b exhibited the best activity against cancer cells. Compound 8b induced apoptosis and blocked the cell cycle. Meanwhile, 8b reduced intracellular ROS content and caused the loss of mitochondrial membrane potential. Further research revealed that 8b significantly blocked STAT3 phosphorylation and STAT3-dependent dual-luciferase reporter gene experiments showed that compound 8b has a marked inhibition of STAT3-mediated Firefly luciferase activity. Molecular modeling studies revealed compound 8b occupied the pocket well with the SH2 domain in a favorable conformation.

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents

The present invention relates to certain novel substituted dihydroimidazo[2,1-b]thiazole and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds of Formula (I) including pharmaceutically acceptable salts thereof in which have affinity for 5-HT1A receptors and which inhibits neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress, as an aid to smoking cessation and in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage.